EMERYVILLE, Calif. -- (BUSINESS WIRE) -- KineMed, Inc. (www.kinemed.com) announced today that Dr. Marc Hellerstein, KineMed’s President and CSO, will give an invited presentation titled “Quantifying in vivo metabolic pathway fluxes and network dynamics using heavy water and mass spectrometry: A new class of disease biomarkers” at the American Association for Cancer Research Annual Meeting, taking place April 5-9, in San Diego, California: http://www.aacr.org/home/scientists/meetings--workshops/aacr-annual-meeting-2014.aspx.
Dr. Hellerstein’s presentation will take place on April 5th, from 4:15 PM to 4:40 PM as part of the workshop titled “Approaches and Challenges in Studying Cancer Metabolism”.
About KineMed, Inc.
KineMed is a growing health technology company that has developed a proprietary biomarker platform technology with broad applications in drug development and medical diagnostics.
Using its patented technology, KineMed has developed analytic biomarker tests which measure, in a single sample, the rate of change of critical biological pathways. KineMed believes that its unique ability to measure the production and destruction of the key molecules involved in disease-modifying biological processes provides meaningful, and previously unavailable, information about both diseases and wellness, which can transform healthcare decisions. KineMed is expanding from its legacy of collaborative pharmaceutical relationships to also establish its own pipeline of therapeutic candidates and diagnostic tests.
For more information about KineMed, please visit: www.kinemed.com